<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nephrotoxicity of chemotherapy and other cytotoxic agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nephrotoxicity of chemotherapy and other cytotoxic agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nephrotoxicity of chemotherapy and other cytotoxic agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jaime R Merchan, MD, MMSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenar D Jhaveri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A variety of kidney diseases and electrolyte disorders can result from the drugs that are used to treat cancer, including chemotherapy, molecularly targeted agents, and immunotherapeutic agents. These drugs can affect the glomerulus, tubules, interstitium, or kidney microvasculature via different mechanisms, with clinical manifestations ranging from an asymptomatic elevation of serum creatinine and electrolyte disorders to acute kidney injury (AKI) requiring dialysis. One study estimated that potentially nephrotoxic drugs were used in 80 percent of chemotherapy sessions [<a href="#rid1">1</a>].</p><p>The nephrotoxicity of select conventional cytotoxic chemotherapy agents will be reviewed here. Kidney toxicities seen with molecularly targeted and biologic agents, drugs that target the vascular endothelial growth factor pathway, and immune checkpoint inhibitors are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Kidney toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'</a>.)</p><p></p><p class="headingAnchor" id="H2914651542"><span class="h1">RISK FACTORS FOR NEPHROTOXICITY</span><span class="headingEndMark"> — </span>Several factors can potentiate kidney function impairment and contribute to the nephrotoxic potential of antineoplastic drugs. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravascular volume depletion, either due to external losses or fluid sequestration (as in ascites or edema). This is one of the most common factors contributing to the nephrotoxic potential of antineoplastic drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The concomitant use of nonchemotherapeutic nephrotoxic drugs (eg, certain antibiotics [including aminoglycoside antibiotics], nonsteroidal antiinflammatory agents, and proton pump inhibitors) or radiographic ionic contrast media in patients with or without preexisting kidney function impairment. (See  <a class="medical medical_review" href="/d/html/7241.html" rel="external">"Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract obstruction secondary to the underlying tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrinsic or acquired kidney disease that is idiopathic, related to other comorbidities, age-related, or related to the cancer itself. (See  <a class="medical medical_review" href="/d/html/89217.html" rel="external">"The aging kidney"</a> and  <a class="medical medical_review" href="/d/html/7173.html" rel="external">"Overview of kidney disease in patients with cancer"</a>.)</p><p></p><p class="headingAnchor" id="H4017014047"><span class="h1">DOSING CONSIDERATIONS FOR NEPHROTOXICITY</span><span class="headingEndMark"> — </span>Some chemotherapy agents may require close monitoring and dose adjustments in patients with baseline kidney disease and those who develop kidney toxicity while on cancer treatment. When known, individual drug dosing guidelines and adjustments for kidney toxicity are available through the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p class="headingAnchor" id="H1464773167"><span class="h1">PLATINUM AGENTS</span></p><p class="headingAnchor" id="H3445642140"><span class="h2">Cisplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> is one of the most commonly used antineoplastic drugs and one of the most nephrotoxic. Cisplatin is associated with acute kidney injury (AKI), thrombotic microangiopathy (TMA), hypomagnesemia, proximal tubular dysfunction (ie, Fanconi-like syndrome), and anemia that is out of proportion to the drug's myelosuppressive effects. Hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity [<a href="#rid2">2</a>]. </p><p>Monitoring and management of cisplatin-induced kidney insufficiency is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.) </p><p class="headingAnchor" id="H3146614886"><span class="h2">Carboplatin</span><span class="headingEndMark"> — </span>In both experimental and clinical studies, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is significantly less nephrotoxic than <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid3">3,4</a>]. This increase in safety may reflect the enhanced stability of carboplatin, which has carboxylate and cyclobutane moieties in the cis position rather than chloride [<a href="#rid4">4</a>]. Hypomagnesemia appears to be the most common manifestation of nephrotoxicity, although it occurs less often than with cisplatin [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p>AKI has been reported, particularly in patients previously treated with several courses of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid4">4</a>]. Direct tubular injury leading to acute tubular necrosis is the primary mechanism. A less common kidney side effect is renal magnesium wasting [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H1492368321"><span class="h2">Oxaliplatin</span><span class="headingEndMark"> — </span>In contrast with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, clinically significant kidney toxicity (such as acute tubular necrosis) occurs rarely with the third-generation platinum compound <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, sometimes in the setting of immune-mediated intravascular hemolysis [<a href="#rid9">9-12</a>]. Limited data with oxaliplatin suggest no exacerbation of pre-existing mild kidney impairment during treatment [<a href="#rid13">13</a>]. Oxaliplatin has been associated with TMA in rare single case reports. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Oxaliplatin'</a>.)</p><p class="headingAnchor" id="H1182090291"><span class="h1">ALKYLATING AGENTS</span></p><p class="headingAnchor" id="H1443878538"><span class="h2">Ifosfamide</span><span class="headingEndMark"> — </span>Similar to <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, the predominant toxicity of <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> on the urinary tract is hemorrhagic cystitis. Ifosfamide can also cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH). (See  <a class="medical medical_review" href="/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients"</a> and  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p>However, nephrotoxicity is more likely with <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> than with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Ifosfamide nephrotoxicity affects the proximal tubule and is characterized by one or more of the following signs of acute tubular dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic acidosis with a normal anion gap (hyperchloremic acidosis) due to type 1 (distal) or type 2 (proximal) renal tubular acidosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypophosphatemia induced by decreased proximal phosphate reabsorption, which can lead to rickets in children</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal glucosuria, aminoaciduria, and a marked increase in beta-2-microglobulin excretion, all from generalized proximal dysfunction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria due to arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia, which may be severe, resulting from increased urinary potassium losses</p><p></p><p>These data on tubular dysfunction come predominantly from pediatric patients treated with <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>. There are few data on long-term kidney function in adults who have received ifosfamide. However, a persistent decline in glomerular filtration rate (GFR) over time has been described after as little as one course of ifosfamide in adults [<a href="#rid14">14</a>]. Prevention and management of nephrotoxicity due to ifosfamide is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2383.html" rel="external">"Ifosfamide nephrotoxicity"</a>.) </p><p class="headingAnchor" id="H1984434136"><span class="h2">Cyclophosphamide</span><span class="headingEndMark"> — </span>The main urologic toxicity of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is hemorrhagic cystitis. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a> and  <a class="medical medical_review" href="/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients"</a>.)</p><p>The primary kidney effect of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is hyponatremia, which is due to an increased effect of antidiuretic hormone (SIADH) impairing the kidney's ability to excrete water [<a href="#rid15">15-17</a>]. Chemotherapy-induced nausea may also play a contributory role since nausea is a potent stimulus to antidiuretic hormone release. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a> and  <a class="medical medical_review" href="/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients"</a>.)</p><p>Hyponatremia is usually seen in patients receiving high doses of intravenous (IV) <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (eg, 30 to 50 mg/kg or 6 g/m<sup>2</sup> in the setting of hematopoietic stem cell transplantation). Although less common, hyponatremia can also occur with oral therapy or with lower IV doses (eg, 10 to 15 mg/kg) given as pulse therapy in autoimmune diseases such as lupus nephritis. (See  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation"</a>.)</p><p>Hyponatremia typically occurs acutely and resolves within approximately 24 hours after discontinuation of the drug. Hyponatremia poses a particular problem for patients undergoing high-dose IV <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, who are often fluid loaded to prevent hemorrhagic cystitis [<a href="#rid17">17</a>]. The combination of increased antidiuretic hormone effect and enhanced water intake can lead to severe, occasionally fatal hyponatremia within 24 hours. This complication can be minimized by using isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> rather than hypotonic solutions to maintain a high urine output. However, hyponatremia can worsen even with isotonic saline administration. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'Therapies to raise the serum sodium'</a>.)</p><p class="headingAnchor" id="H447753913"><span class="h2">Melphalan</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">Melphalan</a> is an alkylating agent that is used mainly for the treatment of multiple myeloma, either as a conditioning regimen prior to hematopoietic cell transplantation or in the palliative setting. Melphalan has been associated with the development of SIADH [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.) </p><p class="headingAnchor" id="H2529906837"><span class="h2">Nitrosureas</span><span class="headingEndMark"> — </span>A slowly progressive, chronic interstitial nephritis that is generally irreversible can be induced by prolonged therapy with the nitrosoureas <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a> (BiCNU), <a class="drug drug_general" data-topicid="9569" href="/d/drug information/9569.html" rel="external">lomustine</a> (CCNU), and <a class="drug drug_general" data-topicid="9949" href="/d/drug information/9949.html" rel="external">streptozocin</a> [<a href="#rid20">20,21</a>]. Although the exact mechanism of nephrotoxicity is not completely elucidated, these agents may produce nephrotoxicity through alkylation of tubular cell proteins. Their metabolites, which are thought to be responsible for nephrotoxicity, persist in the urine for up to 72 hours following administration [<a href="#rid22">22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carmustine</strong> – Although the primary dose-limiting toxicity of <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a> is pulmonary injury, it has been associated with kidney function impairment in several reports [<a href="#rid23">23</a>]. Histologic changes include mild interstitial infiltrates and tubular changes. (See  <a class="medical medical_review" href="/d/html/4354.html" rel="external">"Nitrosourea-induced pulmonary injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Streptozocin</strong> – <a class="drug drug_general" data-topicid="9949" href="/d/drug information/9949.html" rel="external">Streptozocin</a>, a non-myelosuppressive nitrosourea, has been associated with nephrotoxicity in up to 75 percent of patients treated for prolonged periods of time. Although nephrotoxicity is not necessarily dose related, it is rare in patients treated with &lt;1 to 1.5 g/m<sup>2</sup> per week [<a href="#rid24">24</a>]. Streptozocin damages the kidney tubules, causing atrophy and tubulointerstitial nephritis [<a href="#rid25">25</a>]; other case reports describe uric acid nephrolithiasis and acute kidney injury (AKI) [<a href="#rid26">26</a>], and AVP-R (arginine vasopressin resistance, previously known as diabetes insipidus [<a href="#rid27">27</a>]) following streptozocin.</p><p></p><p class="bulletIndent1">Mild proteinuria or an asymptomatic elevation in the plasma creatinine concentration is usually the first sign of kidney involvement, followed by signs of proximal tubular damage (eg, phosphaturia, glycosuria, aminoaciduria, uricosuria, and bicarbonaturia). In one study of 52 patients treated for advanced islet cell carcinoma, the most common sign of nephrotoxicity was proteinuria (51 percent), followed by renal tubular acidosis (17 percent), Fanconi syndrome (13 percent), and azotemia (26 percent) [<a href="#rid28">28</a>]. Nephrotoxicity contributed to death in 11 percent of treated patients.</p><p></p><p>The onset of clinical nephrotoxicity may be delayed from several months to as long as several years after nitrosoureas have been discontinued. As a result, careful long-term follow-up is essential. If it develops, nephrotoxicity typically persists for approximately two to three weeks after the drug is stopped. There is no known therapy for this disorder once it has begun. It has been suggested, however, that the nephrotoxicity can be diminished by the use of forced diuresis (2 liters of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> per hour for two hours) when the drug is being given [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3798242274"><span class="h2">Trabectedin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">Trabectedin</a> is a marine-derived alkylating agent that is approved for treatment of advanced soft tissue sarcoma. Cases of kidney failure (occasionally fatal) have been reported, some of which are attributable to rhabdomyolysis [<a href="#rid30">30-34</a>].</p><p class="headingAnchor" id="H165754186"><span class="h1">ANTIMETABOLITES</span></p><p class="headingAnchor" id="H4130255301"><span class="h2">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> at doses less than 0.5 to 1 g/m<sup>2</sup> is usually not associated with kidney toxicity unless underlying kidney function impairment is present. By contrast, high-dose intravenous (IV) methotrexate (1 to 15 g/m<sup>2</sup>) can precipitate in the tubules and induce tubular injury; at particular risk are patients who are volume depleted and those who excrete acidic urine. Maintenance of adequate urinary output and alkalinization will lessen the probability of methotrexate precipitation. The management of methotrexate kidney toxicity is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Renal toxicity'</a> and  <a class="medical medical_review" href="/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury", section on 'Methotrexate'</a>.)</p><p><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> can also produce a transient decrease in glomerular filtration rate (GFR), with complete recovery within six to eight hours of discontinuing the drug. The mechanism responsible for this functional kidney impairment involves afferent arteriolar constriction or mesangial cell constriction that produces reduced glomerular capillary surface area and diminished glomerular capillary perfusion and pressure [<a href="#rid35">35</a>]. Methotrexate has also been associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p class="headingAnchor" id="H686570949"><span class="h2">Pemetrexed</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> is a derivative of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> that is approved for treatment of advanced non-small cell lung cancer and pleural mesothelioma. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation", section on 'Pemetrexed or docetaxel (with or without ramucirumab)'</a>.)</p><p><a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> has been associated with kidney damage (including acute tubular necrosis, interstitial edema, renal tubular acidosis, and arginine vasopressin resistance [AVP-R, previously known as diabetes insipidus]) [<a href="#rid36">36-38</a>]. The risk of acute kidney injury (AKI) is thought to be low (1 to 5 percent), but higher risks have been reported by others (21 to 54 percent), mainly in patients with non-small cell lung cancer treated with combination chemotherapy that includes pemetrexed [<a href="#rid38">38,39</a>]. The mechanisms of pemetrexed-mediated kidney injury are not completely understood, but several reports suggest tubular injury due to pemetrexed polyglutamation, retention of intracellular polyglutamates, and impairment of nucleic acid synthesis [<a href="#rid40">40</a>]. Baseline kidney function impairment appears to be a risk factor for AKI [<a href="#rid38">38,39</a>]. Some cases may not be reversible [<a href="#rid38">38,39,41</a>]. (See  <a class="medical medical_review" href="/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a>.)</p><p class="headingAnchor" id="H3687148824"><span class="h2">Gemcitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> is a cell cycle-specific pyrimidine antagonist; the most common form of kidney toxicity is AKI with microangiopathic hemolytic anemia (thrombotic microangiopathy [TMA], previously referred to as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome [TTP-HUS]) [<a href="#rid42">42-44</a>]. The incidence ranges from 0.015 to 1.4 percent, and in some reports (but not others [<a href="#rid45">45</a>]), risk is highest in those who have received cumulative gemcitabine doses over 20,000 mg/m<sup>2</sup> [<a href="#rid44">44</a>] Prior therapy with <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> C may be a risk factor for the development of TMA [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a>.)</p><p>The diagnosis of TMA should be considered in a patient who develops Coombs-negative hemolytic anemia, thrombocytopenia, AKI, and/or neurologic findings while receiving <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>. Proteinuria is common but may not occur in all patients with TMA [<a href="#rid46">46</a>]. Management of TMA includes drug discontinuation and supportive care. Further details on the treatment of drug-induced TMA, including anticomplement therapy, is discussed separately. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Management'</a>.)</p><p class="headingAnchor" id="H613867671"><span class="h2">Clofarabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9220" href="/d/drug information/9220.html" rel="external">Clofarabine</a> is a purine nucleoside analog that exerts its antineoplastic effect by inhibiting DNA synthesis and the enzyme ribonucleotide reductase. It is approved for acute lymphoblastic leukemia in children, and it is also being used for relapsed or refractory acute myeloid leukemia and acute lymphoblastic leukemia in adults. (See  <a class="medical medical_review" href="/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Clofarabine'</a> and  <a class="medical medical_review" href="/d/html/4540.html" rel="external">"Treatment of relapsed or refractory acute myeloid leukemia", section on 'Remission re-induction'</a>.)</p><p>Two case reports describe severe kidney injury shortly after drug administration; one patient was found to have 4 g of proteinuria, and the other developed anuria and required dialysis [<a href="#rid47">47,48</a>]. No biopsy data exist to help propose a mechanism of injury in these patients, but ribonucleoside reductase may be contributing to podocyte injury and the development of proteinuria [<a href="#rid47">47</a>].</p><p>The magnitude of nephrotoxicity risk is unclear. In one study, the risk of AKI was as high as 55 percent following use of <a class="drug drug_general" data-topicid="9220" href="/d/drug information/9220.html" rel="external">clofarabine</a> in patients undergoing hematopoietic cell transplantation [<a href="#rid49">49</a>]. Age was the strongest predictor of AKI. The area under the curve of concentration X time (AUC, mg/mL x min) was higher in patients who developed AKI; those with the highest dose-normalized AUCs experienced the most severe grades of AKI. One of those patients had a kidney biopsy that showed acute toxic tubular necrosis as the likely mechanism of injury. (See  <a class="medical medical_review" href="/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a>.)</p><p class="headingAnchor" id="H1880507564"><span class="h1">ANTIMICROTUBULE AGENTS</span></p><p class="headingAnchor" id="H2039383688"><span class="h2">Taxanes</span><span class="headingEndMark"> — </span>The taxanes <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> have not been associated with nephrotoxicity.</p><p><a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">Cabazitaxel</a> is a semisynthetic taxane. Cases of kidney failure were reported in a randomized trial conducted in men with metastatic prostate cancer, including four with a fatal outcome. Most occurred in association with sepsis, dehydration, or obstructive uropathy. Hemorrhagic cystitis has also been reported. (See  <a class="medical medical_review" href="/d/html/6945.html" rel="external">"Chemotherapy in advanced castration-resistant prostate cancer", section on 'Men who have received prior docetaxel'</a> and  <a class="medical medical_review" href="/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients", section on 'Chemotherapy'</a>.)</p><p class="headingAnchor" id="H2883276465"><span class="h2">Vinca alkaloids</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">Vincristine</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a> have all been associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a small number of treated patients [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p class="headingAnchor" id="H3988876155"><span class="h1">ANTITUMOR ANTIBIOTICS</span></p><p class="headingAnchor" id="H1231340924"><span class="h2">Anthracyclines and related agents</span><span class="headingEndMark"> — </span>Anthracyclines such as <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> have been known to cause nephrotic syndrome with kidney lesions consistent with minimal change disease, focal segmental glomerular sclerosis not otherwise specified (NOS), or collapsing glomerulopathy [<a href="#rid52">52</a>]. In addition, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> has been associated with renal thrombotic microangiopathy (TMA), nephrotic syndrome, and acute kidney injury (AKI) [<a href="#rid53">53-55</a>]. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a>.)</p><p class="headingAnchor" id="H168841007"><span class="h2">Mitomycin</span><span class="headingEndMark"> — </span>There is a possible association of <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> with drug-induced TMA that has not been definitively established. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a>.)</p><p class="headingAnchor" id="H817535237"><span class="h1">IMMUNOMODULATORY DRUGS</span><span class="headingEndMark"> — </span>Immunomodulatory imide drugs (IMiDs), which include <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a>, are used for the treatment of relapsed or recurrent multiple myeloma, a disease that frequently is associated with kidney impairment. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Immunomodulatory drugs'</a> and  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse", section on 'Lenalidomide sensitive'</a>.)</p><p class="headingAnchor" id="H510728191"><span class="h2">Thalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a>, a first-generation IMiD, is metabolized via nonenzymatic hydrolysis, and &lt;1 percent of the unchanged drug is excreted in the urine [<a href="#rid56">56</a>]. In the initial report showing thalidomide activity against multiple myeloma, 8 out of 84 patients had a &gt;50 percent increase in serum creatinine; however, the kidney injury was attributed to underlying disease progression and not drug-related toxicity [<a href="#rid57">57</a>]. In clinical practice, the use of thalidomide has not been associated with clinically significant acute kidney injury (AKI). However, there are reports of otherwise unexplained hyperkalemia in patients with myeloma treated with thalidomide [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H1317302164"><span class="h2">Lenalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> is an analog of <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> that, in contrast with thalidomide, is predominantly excreted in the urine as unchanged drug. </p><p>Cases of lenalidomide-induced AKI have been reported, including a case of biopsy-proven acute interstitial nephritis [<a href="#rid60">60,61</a>]. In a series of 41 patients with immunoglobulin light chain amyloidosis who were treated with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, 27 (66 percent) developed kidney function impairment (defined as a ≥50 percent increase in serum creatinine) during treatment, including four of the eight patients without underlying renal amyloidosis [<a href="#rid62">62</a>]. Severe kidney function impairment occurred in 13 patients (32 percent), four of whom required dialysis. The median time to kidney function impairment after starting lenalidomide was 44 days (interquartile range 15 to 108 days).</p><p>Other types of kidney injury have been reported but seem to be rare overall:</p><p class="bulletIndent1"><span class="glyph">●</span>At least one patient has developed Fanconi syndrome (generalized proximal tubular dysfunction characterized by phosphaturia, renal glucosuria, aminoaciduria, tubular proteinuria, and proximal renal tubular acidosis) while receiving <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One patient has been described with acute interstitial nephritis and a drug reaction with eosinophilia, rash, and systemic symptoms (DRESS syndrome) [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A case of minimal change disease was reported in a patient with Waldenström macroglobulinemia being treated with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> has multiple immunomodulatory effects, and activation of the immune system may result in immune-mediated complications. As examples, there have been several case reports of acute allograft rejection after treatment with this drug [<a href="#rid66">66-68</a>]. (See  <a class="medical medical_review" href="/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1457063483"><span class="h2">Pomalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> is a second-generation IMiD that is used for treatment of multiple myeloma and Kaposi sarcoma. (See  <a class="medical medical_review" href="/d/html/7729.html" rel="external">"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment", section on 'Pomalidomide'</a> and  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse", section on 'Bortezomib, pomalidomide, dexamethasone (VPd)'</a>.) </p><p><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> is predominantly metabolized by the liver. In one of the three trials that evaluated its efficacy in multiple myeloma, the incidence of grade 3 to 4 kidney toxicity  (<a class="graphic graphic_table graphicRef91253" href="/d/graphic/91253.html" rel="external">table 1</a>) was 5.9 percent [<a href="#rid69">69</a>]. In addition, a single case of AKI with crystal nephropathy was attributed to pomalidomide; however, the confounding factors included concurrent use of <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, which may have contributed to both the AKI and the crystal formation [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2749680856"><span class="h1">PROTEASOME INHIBITORS</span><span class="headingEndMark"> — </span>Proteasome inhibitors block the action of proteasomes, which are enzyme complexes responsible for the degradation of intracellular proteins. These agents have been approved for use in the treatment of multiple myeloma. (See  <a class="medical medical_review" href="/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a> and  <a class="medical medical_review" href="/d/html/85687.html" rel="external">"Treatment protocols for multiple myeloma"</a> and  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Proteasome inhibitors'</a>.)</p><p class="headingAnchor" id="H1615320468"><span class="h2">Carfilzomib</span><span class="headingEndMark"> — </span>There have been reports of creatinine elevations in up to 25 percent of patients treated with <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase II study of 266 patients with relapsed and refractory myeloma treated with single-agent <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, acute kidney injury (AKI) was reported in 25 percent [<a href="#rid71">71</a>]. Although the majority of kidney adverse effects were mild, progressive kidney disease occurred in 3.8 percent of patients, leading to discontinuation of the drug in two patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another phase III trial of patients with relapsed or refractory multiple myeloma who received <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a> or a control regimen of low-dose glucocorticoids with optional <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, the incidence of grade 3 AKI  (<a class="graphic graphic_table graphicRef91253" href="/d/graphic/91253.html" rel="external">table 1</a>) was higher in the carfilzomib arm (8 versus 3 percent) [<a href="#rid72">72</a>]. Kidney adverse events of any type also occurred more frequently in the carfilzomib group (24 versus 9 percent); in both groups, these events were more likely to occur among patients with lower creatinine clearance (CrCl; &lt;30 mL/min) and in those with evidence of a urine monoclonal protein.</p><p></p><p>Potential mechanisms for AKI in patients treated with <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a> include prerenal causes (eg, hypovolemia), tumor lysis-like syndrome, or acute tubular necrosis [<a href="#rid73">73-78</a>]. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a> and  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Less common causes of albuminuria'</a>.)</p><p>Thrombotic microangiopathy (TMA) has also been described in patients treated with <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>. In one case series, the median time between drug initiation and diagnosis was 21 days (range 5 days to 17 months), and the majority had complete resolution of TMA after discontinuation of the proteasome inhibitor [<a href="#rid79">79-81</a>]. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a>.)</p><p class="headingAnchor" id="H1482192660"><span class="h2">Bortezomib</span><span class="headingEndMark"> — </span>In general, nephrotoxicity is uncommon with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, although several cases of TMA have been reported. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a>.)</p><p>In addition, a case of biopsy-proven acute interstitial nephritis with granuloma formation has been described [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H275144800"><span class="h2">Ixazomib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">Ixazomib</a> is an orally active proteasome inhibitor; as with other proteasome inhibitors, TMA has been reported rarely [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a>.)</p><p class="headingAnchor" id="H42"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– Several factors can potentiate kidney function impairment and contribute to the nephrotoxic potential of antineoplastic drugs. These include intravascular volume depletion, concomitant use of nonchemotherapeutic nephrotoxic drugs or radiographic ionic contrast media, urinary tract obstruction secondary to the underlying tumor, and intrinsic or acquired kidney disease. (See <a class="local">'Risk factors for nephrotoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing considerations </strong>– Some chemotherapy agents may require close monitoring and dose adjustments in patients with baseline kidney disease and those who develop kidney toxicity while on cancer treatment. When known, individual drug dosing guidelines and adjustments for kidney toxicity are available through the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See <a class="local">'Dosing considerations for nephrotoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrotoxicity of conventional cytotoxic agents</strong> – The kidney toxicities of different classes of conventional cytotoxic agents are described in detail above. Selected agents are highlighted below:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Platinum agents </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cisplatin</strong> - <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a>, one of the most commonly used antineoplastic drugs, is associated with acute kidney injury (AKI), thrombotic microangiopathy (TMA), hypomagnesemia, proximal tubular dysfunction (ie, Fanconi-like syndrome), and anemia that is out of proportion to the drug's myelosuppressive effects. (See <a class="local">'Cisplatin'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Carboplatin</strong> - <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">Carboplatin</a> is less nephrotoxic than <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, but hypomagnesemia and AKI can occur. (See <a class="local">'Carboplatin'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Oxaliplatin</strong> - Clinically significant kidney toxicity is rare with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>. (See <a class="local">'Oxaliplatin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ifosfamide</strong><strong> </strong>– <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">Ifosfamide</a> nephrotoxicity is manifested by signs of proximal tubular dysfunction including glucosuria, aminoaciduria, tubular proteinuria (ie, increased urine excretion of low-molecular-weight proteins such as beta-2-microglobulin, but not of albumin), and, rarely, polyuria due to arginine vasopressin resistance (AVP-R, previously known as diabetes insipidus). Ifosfamide can also cause hemorrhagic cystitis. (See <a class="local">'Ifosfamide'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methotrexate</strong><strong> </strong>– High-dose intravenous (IV) <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (1 to 15 g/m<sup>2</sup>) can precipitate in the tubules and induce tubular injury, particularly in patients who are volume depleted and those who excrete acidic urine. Methotrexate at doses less than 0.5 to 1 g/m<sup>2</sup> is usually not associated with kidney toxicity unless underlying kidney function impairment is present. (See <a class="local">'Methotrexate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pemetrexed</strong><strong> </strong>– <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> has been associated with kidney damage including acute tubular necrosis, interstitial edema, renal tubular acidosis, and AVP-R. (See <a class="local">'Pemetrexed'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gemcitabine</strong><strong> </strong>– The most common form of kidney toxicity with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> is AKI with microangiopathic hemolytic anemia (TMA). The risk is highest in those who have received cumulative gemcitabine doses over 20,000 mg/m<sup>2</sup>. (See <a class="local">'Gemcitabine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Proteosome inhibitors </strong>– Proteosome inhibitors, including <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, and <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">ixazomib</a>, have been associated with the development of TMA. (See <a class="local">'Proteasome inhibitors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376.</a></li><li><a class="nounderline abstract_t">Crona DJ, Faso A, Nishijima TF, et al. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist 2017; 22:609.</a></li><li><a class="nounderline abstract_t">Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8:368.</a></li><li><a class="nounderline abstract_t">McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med 1991; 90:386.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Williston Park) 1991; 5:97.</a></li><li><a class="nounderline abstract_t">Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994; 73:1297.</a></li><li><a class="nounderline abstract_t">Tscherning C, Rubie H, Chancholle A, et al. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994; 73:1761.</a></li><li><a class="nounderline abstract_t">Welborn J, Meyers FJ, O'Grady LF. Renal salt wasting and carboplatinum. Ann Intern Med 1988; 108:640.</a></li><li><a class="nounderline abstract_t">Lévi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38:1.</a></li><li><a class="nounderline abstract_t">Pinotti G, Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol 2002; 13:1951.</a></li><li><a class="nounderline abstract_t">Labaye J, Sarret D, Duvic C, et al. Renal toxicity of oxaliplatin. Nephrol Dial Transplant 2005; 20:1275.</a></li><li><a class="nounderline abstract_t">Ulusakarya A, Misra S, Haydar M, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol 2010; 27:1425.</a></li><li><a class="nounderline abstract_t">Chollet P, Bensmaïne MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7:1065.</a></li><li><a class="nounderline abstract_t">Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients--5 year data. Eur J Cancer 2012; 48:1326.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Colvin OM, Braine H, et al. Proceedings: Cyclophosphamide and the kidney. Cancer 1974; 33:483.</a></li><li><a class="nounderline abstract_t">Bode U, Seif SM, Levine AS. Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. Med Pediatr Oncol 1980; 8:295.</a></li><li><a class="nounderline abstract_t">Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145:548.</a></li><li><a class="nounderline abstract_t">Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB, et al. Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. Cancer 1985; 55:44.</a></li><li><a class="nounderline abstract_t">Helson L, Sadof MD, Wernovsky G, Gulati S. L-phenylalanine mustard-dianhydrogalactitol and hyponatremia. Pediatr Hematol Oncol 1986; 3:287.</a></li><li><a class="nounderline abstract_t">Harmon WE, Cohen HJ, Schneeberger EE, Grupe WE. Chronic renal failure in children treated with methyl CCNU. N Engl J Med 1979; 300:1200.</a></li><li><a class="nounderline abstract_t">Narins RG, Carley M, Bloom EJ, Harrison DS. The nephrotoxicity of chemotherapeutic agents. Semin Nephrol 1990; 10:556.</a></li><li><a class="nounderline abstract_t">Sponzo RW, DeVita VT, Oliverio VT. Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man. Cancer 1973; 31:1154.</a></li><li><a class="nounderline abstract_t">Schacht RG, Feiner HD, Gallo GR, et al. Nephrotoxicity of nitrosoureas. Cancer 1981; 48:1328.</a></li><li><a class="nounderline abstract_t">Sadoff L. Nephrotoxicity of streptozotocin (NSC-85998). Cancer Chemother Rep 1970; 54:457.</a></li><li><a class="nounderline abstract_t">Myerowitz RL, Sartiano GP, Cavallo T. Nephrotoxic and cytoproliferative effects of streptozotocin: report of a patient with multiple hormone-secreting islet cell carcinoma. Cancer 1976; 38:1550.</a></li><li><a class="nounderline abstract_t">Hricik DE, Goldsmith GH. Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. Am J Med 1988; 84:153.</a></li><li><a class="nounderline abstract_t">Delaney V, de Pertuz Y, Nixon D, Bourke E. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. Am J Kidney Dis 1987; 9:79.</a></li><li><a class="nounderline abstract_t">Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79:108.</a></li><li><a class="nounderline abstract_t">Tobin MV, Warenius HM, Morris AI. Forced diuresis to reduce nephrotoxicity of streptozotocin in the treatment of advanced metastatic insulinoma. Br Med J (Clin Res Ed) 1987; 294:1128.</a></li><li><a class="nounderline abstract_t">Pick AM, Nystrom KK. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma. J Oncol Pharm Pract 2010; 16:269.</a></li><li><a class="nounderline abstract_t">Skorupa A, Beldner M, Kraft A, Montero AJ. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther 2007; 6:1015.</a></li><li><a class="nounderline abstract_t">Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001; 7:231.</a></li><li><a class="nounderline abstract_t">Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890.</a></li><li><a class="nounderline abstract_t">Stoyianni A, Kapodistrias N, Kampletsas E, et al. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori 2011; 97:252.</a></li><li><a class="nounderline abstract_t">Howell SB, Carmody J. Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults. Cancer Treat Rep 1977; 61:1389.</a></li><li><a class="nounderline abstract_t">Stavroulopoulos A, Nakopoulou L, Xydakis AM, et al. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 2010; 32:1000.</a></li><li><a class="nounderline abstract_t">Vootukuru V, Liew YP, Nally JV Jr. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 2006; 23:419.</a></li><li><a class="nounderline abstract_t">Zattera T, Londrino F, Trezzi M, et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J Nephropathol 2017; 6:43.</a></li><li><a class="nounderline abstract_t">Rombolà G, Vaira F, Trezzi M, et al. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage. J Nephrol 2015; 28:187.</a></li><li><a class="nounderline abstract_t">Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012; 7:1713.</a></li><li><a class="nounderline abstract_t">Visser S, Huisbrink J, van 't Veer NE, et al. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J 2018; 52.</a></li><li><a class="nounderline abstract_t">Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006; 21:3038.</a></li><li><a class="nounderline abstract_t">Glezerman I, Kris MG, Miller V, et al. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 2009; 71:130.</a></li><li><a class="nounderline abstract_t">Saif MW, Xyla V, Makrilia N, et al. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf 2009; 8:257.</a></li><li><a class="nounderline abstract_t">Leal F, Macedo LT, Carvalheira JB. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series. J Chemother 2014; 26:169.</a></li><li><a class="nounderline abstract_t">Dopson SJ, Ullian ME. Proteinuria in patients with thrombotic thrombocytopenic purpura. Nephrology Research &amp; Reviews 2011; 3:1.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Chidella S, Allen SL, Fishbane S. Clofarabine-induced kidney toxicity. J Oncol Pharm Pract 2014; 20:305.</a></li><li><a class="nounderline abstract_t">Kintzel PE, Visser JA, Campbell AD. Clofarabine-associated acute kidney injury and proteinuria. Pharmacotherapy 2011; 31:923.</a></li><li><a class="nounderline abstract_t">Petri CR, O'Donnell PH, Cao H, et al. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma 2014; 55:2866.</a></li><li><a class="nounderline abstract_t">Cutting HO. Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy. Am J Med 1971; 51:269.</a></li><li><a class="nounderline abstract_t">Garrett CA, Simpson TA Jr. Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. Ann Pharmacother 1998; 32:1306.</a></li><li><a class="nounderline abstract_t">Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 2013; 61:778.</a></li><li><a class="nounderline abstract_t">Shavit L, Lifschitz MD, Gabizon A, et al. Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. Kidney Int 2014; 85:213.</a></li><li><a class="nounderline abstract_t">Kwa M, Baumgartner R, Shavit L, et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 2012; 17:1534.</a></li><li><a class="nounderline abstract_t">Carron PL, Padilla M, Maurizi Balzan J. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment. Hemodial Int 2014; 18:846.</a></li><li><a class="nounderline abstract_t">Chung F, Lu J, Palmer BD, et al. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res 2004; 10:5949.</a></li><li><a class="nounderline abstract_t">Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565.</a></li><li><a class="nounderline abstract_t">Harris E, Behrens J, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003; 122:160.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Guerraoui H, Presne C, et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 2004; 125:96.</a></li><li><a class="nounderline abstract_t">Lipson EJ, Huff CA, Holanda DG, et al. Lenalidomide-induced acute interstitial nephritis. Oncologist 2010; 15:961.</a></li><li><a class="nounderline abstract_t">Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008; 49:1108.</a></li><li><a class="nounderline abstract_t">Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011; 26:881.</a></li><li><a class="nounderline abstract_t">Glezerman IG, Kewalramani T, Jhaveri K. Reversible Fanconi syndrome due to lenalidomide. NDT Plus 2008; 1:215.</a></li><li><a class="nounderline abstract_t">Shaaban H, Layne T, Guron G. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. J Oncol Pharm Pract 2014; 20:302.</a></li><li><a class="nounderline abstract_t">Jamme M, Galichon P, Hertig A. Minimal change disease and lenalidomide. Am J Kidney Dis 2013; 62:844.</a></li><li><a class="nounderline abstract_t">Walavalkar V, Adey DB, Laszik ZG, Jen KY. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report. Transplant Proc 2018; 50:873.</a></li><li><a class="nounderline abstract_t">Lum EL, Huang E, Bunnapradist S, et al. Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma. Am J Kidney Dis 2017; 69:701.</a></li><li><a class="nounderline abstract_t">Meyers DE, Adu-Gyamfi B, Segura AM, et al. Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis. Am J Transplant 2013; 13:2730.</a></li><li><a class="nounderline abstract_t">Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123:1826.</a></li><li><a class="nounderline abstract_t">Baird P, Leung S, Hoang H, et al. A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. J Oncol Pharm Pract 2016; 22:357.</a></li><li><a class="nounderline abstract_t">Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120:2817.</a></li><li><a class="nounderline abstract_t">Hájek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 2017; 31:107.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Chidella S, Varghese J, et al. Carfilzomib-related acute kidney injury. Clin Adv Hematol Oncol 2013; 11:604.</a></li><li><a class="nounderline abstract_t">Wanchoo R, Khan S, Kolitz JE, Jhaveri KD. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. J Oncol Pharm Pract 2015; 21:313.</a></li><li><a class="nounderline abstract_t">Shely RN, Ratliff PD. Carfilzomib-associated tumor lysis syndrome. Pharmacotherapy 2014; 34:e34.</a></li><li><a class="nounderline abstract_t">Liberman V, D'Agati VD, Masani NN, et al. Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib. Kidney Int Rep 2016; 1:89.</a></li><li><a class="nounderline abstract_t">Sullivan MR, Danilov AV, Lansigan F, Dunbar NM. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher 2015; 30:308.</a></li><li><a class="nounderline abstract_t">Hobeika L, Self SE, Velez JC. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 2014; 15:156.</a></li><li><a class="nounderline abstract_t">Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol 2016; 91:E348.</a></li><li><a class="nounderline abstract_t">Klomjit N, Evans R, Le TK, et al. Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database. Am J Hematol 2023; 98:E369.</a></li><li><a class="nounderline abstract_t">Moscvin M, Liacos CI, Chen T, et al. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer J 2023; 13:31.</a></li><li><a class="nounderline abstract_t">Cheungpasitporn W, Leung N, Rajkumar SV, et al. Bortezomib-induced acute interstitial nephritis. Nephrol Dial Transplant 2015; 30:1225.</a></li><li><a class="nounderline abstract_t">Yui JC, Dispenzieri A, Leung N. Ixazomib-induced thrombotic microangiopathy. Am J Hematol 2017; 92:E53.</a></li></ol></div><div id="topicVersionRevision">Topic 2834 Version 95.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634949" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28438887" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3538860" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2003521" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1838278" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nephrotoxicity from chemotherapy: prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8313334" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156505" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recurrent renal salt wasting in a child treated with carboplatin and etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3279897" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal salt wasting and carboplatinum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668856" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oxaliplatin: pharmacokinetics and chronopharmacological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12453866" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A case of acute tubular necrosis due to oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827046" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renal toxicity of oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19565364" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute renal failure related to oxaliplatin-induced intravascular hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037366" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503397" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long term renal toxicity of ifosfamide in adult patients--5 year data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4812765" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Proceedings: Cyclophosphamide and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7464688" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977522" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Water intoxication following moderate-dose intravenous cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965085" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3153241" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : L-phenylalanine mustard-dianhydrogalactitol and hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/431647" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chronic renal failure in children treated with methyl CCNU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2255813" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The nephrotoxicity of chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4705152" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7272960" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nephrotoxicity of nitrosoureas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4334090" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nephrotoxicity of streptozotocin (NSC-85998).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/186169" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nephrotoxic and cytoproliferative effects of streptozotocin: report of a patient with multiple hormone-secreting islet cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2827466" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2949606" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Indomethacin in streptozocin-induced nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4352784" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3034373" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Forced diuresis to reduce nephrotoxicity of streptozotocin in the treatment of advanced metastatic insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015930" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17611408" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234874" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990645" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617727" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/303938" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20722569" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018900" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28491851" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24986522" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879440" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Onco-nephrology: renal toxicities of chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139775" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968717" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gemcitabine-induced thrombotic microangiopathy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203505" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19505260" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Thrombotic microangiopathy associated with gemcitabine: rare but real.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24091354" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Proteinuria in patients with thrombotic thrombocytopenic purpura</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24081220" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clofarabine-induced kidney toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21923594" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clofarabine-associated acute kidney injury and proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24564572" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5095530" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876812" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219112" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Collapsing glomerulopathy following anthracycline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24380911" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622146" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25040096" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355928" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10564685" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antitumor activity of thalidomide in refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823359" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15015981" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thalidomide in patients with multiple myeloma and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709889" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Lenalidomide-induced acute interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452093" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Azotemia associated with use of lenalidomide in plasma cell dyscrasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693160" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Kidney dysfunction during lenalidomide treatment for AL amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25983885" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Reversible Fanconi syndrome due to lenalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999760" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891359" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Minimal change disease and lenalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29661456" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28189378" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23914832" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24421329" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25591868" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22833546" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27416912" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518527" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Carfilzomib-related acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24748581" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24390940" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Carfilzomib-associated tumor lysis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142917" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25413611" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267524" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27286661" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Proteasome inhibitor associated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37740927" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36849497" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26109684" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Bortezomib-induced acute interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28133842" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Ixazomib-induced thrombotic microangiopathy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
